最新の一覧

*, Corresponding Author

Omori K, Nakamura A, Miyoshi H, Yamauchi Y, Kawata S, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Terauchi Y, Atsumi T. Glucokinase inactivation paradoxically ameliorates glucose intolerance by increasing beta-cell mass in db/db mice. Diabetes. 70:917-931, 2021

Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Favorable effect of the SGLT2 inhibitor canagliflozin plus the DPP-4 inhibitor teneligliptin in combination on glycemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). Daiabetes Obes Metab. 22: 458-462, 2020

Cho KY, Nomoto H, Nakamura A, Omori K, Takase T, Miya A, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. SGLT2 inhibitor Dapagliflozin in Superior to Pioglitazone in Improvement of Nonalcoholic Fatty Liver Disease. Daiabetes Invest. in press

Miyoshi A, Kameda H, Nagai S, Nakamura A, Miya A, Takase T, Atsumi T, Miyoshi H*. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteoporosis. J Diabetes Invest. 2020 in press

Kameda R, Nomoto H, Cho KY, Kawata S, Omori K, Takeuchi J, Nagai S, Kurihara Y, Aoki S, Nakamura A, Atsumi T, Miyoshi H. Effect of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin  on nocturnal blood pressure in patients with type 2 diabetes: protocol  for a multicenter, prospective, randomized, open-label, blinded endpoint parallel-group comparison study.  BMJ Open. 10(2): e034883, 2020

Nakamura A,  Miyoshi H, Kameda H, Yamashita K, Kurihara Y. Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria.  Diabetol Metab Syndr. 12:4.2020

Oba-Yamamoto C, Takeuchi J, Nakamura A, Takikawa R, Ozaki A, Nomoto H, Kameda H, Cho KY, Atsumi T, Miyoshi H. Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia.  J Diabetes Invest. 12:651-657, 2021

Cho KY, Nakamura A, Yamamoto C, Tsuchida K, Yanagiya S, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Switching to once-daily insulin degludec/insulin aspart from basal insulin improves postprandial glycemia in patients with type2 diabetes: randomized controlled trial. Diabetes & Metabolism Journal. 44:532-541, 2020

Chiba K, Nomoto H, Nakamura A, Cho KY, Miya A, Kameda H, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. SGLT2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.  J Diabetes Invest. 12:176-183, 2021

Miya A, Nakamura A,  Miyoshi H, Ukawa S, Nakamura A, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Correlation between serum proinsulin levels and fatty liver: the DOSANCO Health Study.  J Diabetes Invest. 11:964-970, 2020

Baba N, Kameda H, Nakamura A, Cho KY, Nomoto H, Mitsuhashi T,  Miyoshi H, Atsumi T. Silent pituitary and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dislipidemia.  Endocrine J. 68:195-200, 2021

Takase T, Nakamura A, Handa T, Nomoto H, Kameda H, Cho KY, Nagai S, Miyoshi H, Atsumi T. Effects of Palmaria palmate on lipid metabolism and glycemic control in participants with hypercholesterolemia in a randomized double-blind placebo-controlled trial.  Phytotherapy Reseach 34:2303-2312, 2020

Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Terauchi Y, Tamakoshi A, Atsumi T. Inverse association between serum high-molecular-weight adiponectin level and proinsulin level in a general Japanese population: the DOSANCO Health Study. J Diabetes Invest. 12:63-66, 2021

Kameda R, Nomoto H, Cho KY, Kawata S, Omori K, Takeuchi J, Nagai S, Kurihara Y, Aoki S, Nakamura A, Atsumi T,Miyoshi H, Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicenter, prospective, randomized, open-label, blinded endpoint parallel-group comparison study. BMJ Open. 10(2):e034883, 2020

Miya A, Nakamura A,  Miyoshi H, Ukawa S, Nakamura A, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Correlation between serum proinsulin levels and fatty liver: the DOSANCO Health Study.  J Diabetes Invest. 11:964-970, 2020

TakaseT, Nakamura A, Miyoshi H, Koga M, Toyomaki A, Kusumi I, Kino R, Konishi Y, Kiso Y, Atsumi T. Effects of Palmaria palmata on lipid metabolism and glycemic control in participants with hypercholesterolemia in a randomized double-blind placebo-controlled trial. Phytotherapy Research 34:2303-2312, 2020

Higuchi I, Kimura Y, Kobayashi M, Miyoshi H, Nakamura A, Atsumi T, Iseki K. Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population. Drug Metab Pharmacokinet.  35:131-138, 2020

Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. Diabetes Obes Metab. 21: 710-714, 2019

Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. Diabetes Obes Metab. 21: 710-714, 2019

Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y. The protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease, and type 2 diabetes. J Diabetes Invest. 10:1510-1517, 2019